» Articles » PMID: 39396907

Efficacy of Weekly Versus Daily Cholecalciferol for Repleting Serum Vitamin D (25(OH)D) Deficiency: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Overview
Specialties Pharmacology
Toxicology
Date 2024 Oct 13
PMID 39396907
Authors
Affiliations
Soon will be listed here.
Abstract

Background/rationale: Weekly cholecalciferol can replace daily supplementation to reduce pill burden in patients with complex medication regimens and hypovitaminosis D, but evidence supporting this switch is unclear.

Objective: We aimed to determine whether weekly cholecalciferol was superior to daily cholecalciferol to replete patients with hypovitaminosis D.

Methods: We conducted a systematic review of randomized controlled trials involving participants with baseline hypovitaminosis D (<30 ng/ml) comparing weekly versus daily cholecalciferol dosing and where serum cholecalciferol was measured within 120 days of starting treatment. We searched MEDLINE, CINAHL and EMBASE from inception to 7 May 2024. A random-effects meta-analysis evaluated the odds ratio for repletion of serum vitamin D levels.

Findings: Eight trials involving 542 patients were included in the analysis. Weekly and daily cholecalciferol were not significantly different in correcting hypovitaminosis D (OR = 1.5, 95% CI = 0.3-6.9, p = 0.6, favouring weekly dosing, I = 85.3%). A sensitivity analysis excluding otherwise healthy patients had similar findings (OR = 0.8, 95% CI = 0.3-2.1, p = 0.6). Most studies were at risk of bias; the different doses being compared increased the heterogeneity.

Conclusions: Limited direct evidence supports a switch from daily to weekly cholecalciferol dosing; however, weekly supplementation was not demonstrably worse at repleting levels and decreased a patient's daily pill burden.

Citing Articles

Efficacy of weekly versus daily cholecalciferol for repleting serum vitamin D (25(OH)D) deficiency: A systematic review and meta-analysis of randomized controlled trials.

Bortolussi-Courval E, Prosty C, Lee J, McCarthy L, McDonald E, Lee T Basic Clin Pharmacol Toxicol. 2024; 135(6):685-692.

PMID: 39396907 PMC: 11617645. DOI: 10.1111/bcpt.14092.

References
1.
Singh V, Misra A, Singh M, Midha N, Kumar B, Ambwani S . An open-label, randomized, 10 weeks prospective study on the efficacy of vitamin D (daily low dose and weekly high dose) in vitamin D deficient patients. J Family Med Prim Care. 2019; 8(6):1958-1963. PMC: 6618212. DOI: 10.4103/jfmpc.jfmpc_272_19. View

2.
Cosman F, de Beur S, LeBoff M, Lewiecki E, Tanner B, Randall S . Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014; 25(10):2359-81. PMC: 4176573. DOI: 10.1007/s00198-014-2794-2. View

3.
Khawaja N, Liswi M, El-Khateeb M, Hyassat D, Bajawi D, Elmohtaseb M . Vitamin D Dosing Strategies Among Jordanians With Hypovitaminosis D. J Pharm Pract. 2016; 30(2):172-179. DOI: 10.1177/0897190015626334. View

4.
Shi L, Chu H, Lin L . A Bayesian approach to assessing small-study effects in meta-analysis of a binary outcome with controlled false positive rate. Res Synth Methods. 2020; 11(4):535-552. PMC: 7343620. DOI: 10.1002/jrsm.1415. View

5.
Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View